MX2021015425A - Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa. - Google Patents
Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa.Info
- Publication number
- MX2021015425A MX2021015425A MX2021015425A MX2021015425A MX2021015425A MX 2021015425 A MX2021015425 A MX 2021015425A MX 2021015425 A MX2021015425 A MX 2021015425A MX 2021015425 A MX2021015425 A MX 2021015425A MX 2021015425 A MX2021015425 A MX 2021015425A
- Authority
- MX
- Mexico
- Prior art keywords
- stereoisomers
- dioxol
- oxazol
- pyrazine
- dione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a los compuestos 3- (benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1H-indol-3 -il)-6,7-dihidro-3H-oxazol[3,4-a]pirazina-5,8-diona de fórmula (I)), (ver Fórmula) y también a estereoisómeros, sales, solvatos, hidratos, profármacos y ésteres de los mismos farmacéuticamente aceptables; estando los estereoisómeros en sus formas individuales separadas y/o en forma de mezclas racémicas o mezclas no racémicas con exceso diastereomérico en cualquier proporción, a una composición farmacéutica que comprende al menos uno de los compuestos descritos; al uso de dichos estereoisómeros como agente antitumoral o inhibidor de la enzima fosfodiesterasa, y al uso de dichos estereoisómeros en el tratamiento de hiperplasia benigna de próstata y cáncer, más específicamente el cáncer de próstata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962874321P | 2019-07-15 | 2019-07-15 | |
PCT/BR2020/050259 WO2021007636A1 (pt) | 2019-07-15 | 2020-07-14 | Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1 h-indol-3-il)-6,7-dihidro-3 h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015425A true MX2021015425A (es) | 2022-02-21 |
Family
ID=74209603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015425A MX2021015425A (es) | 2019-07-15 | 2020-07-14 | Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220296590A1 (es) |
EP (1) | EP4001282A4 (es) |
JP (1) | JP2022540866A (es) |
KR (1) | KR20220035048A (es) |
CN (1) | CN114158266A (es) |
AR (1) | AR119407A1 (es) |
BR (1) | BR112021024894A2 (es) |
CA (1) | CA3144770A1 (es) |
IL (1) | IL288971A (es) |
MX (1) | MX2021015425A (es) |
WO (1) | WO2021007636A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635178A (en) | 1970-04-17 | 1972-01-18 | Home Curtain Corp | Machine for making shirred curtains |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
AU9128998A (en) | 1997-09-04 | 1999-03-22 | Richardson Labs, Inc. | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis |
UY33535A (es) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona |
US8673914B2 (en) * | 2011-03-28 | 2014-03-18 | St. John's University | Use of phosphodiesterase inhibitors for treating multidrug resistance |
AR099523A1 (es) * | 2014-02-24 | 2016-07-27 | Biolab Sanus Farmacêutica Ltda | Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona |
US11464778B2 (en) * | 2017-12-26 | 2022-10-11 | Liqmeds Worldwide Limited | Liquid oral formulations for sildenafil |
-
2020
- 2020-07-14 CN CN202080051067.1A patent/CN114158266A/zh active Pending
- 2020-07-14 KR KR1020217043172A patent/KR20220035048A/ko unknown
- 2020-07-14 WO PCT/BR2020/050259 patent/WO2021007636A1/pt unknown
- 2020-07-14 CA CA3144770A patent/CA3144770A1/en active Pending
- 2020-07-14 US US17/626,635 patent/US20220296590A1/en active Pending
- 2020-07-14 JP JP2022502020A patent/JP2022540866A/ja active Pending
- 2020-07-14 MX MX2021015425A patent/MX2021015425A/es unknown
- 2020-07-14 BR BR112021024894A patent/BR112021024894A2/pt unknown
- 2020-07-14 EP EP20839690.3A patent/EP4001282A4/en active Pending
- 2020-07-15 AR ARP200101981A patent/AR119407A1/es unknown
-
2021
- 2021-12-13 IL IL288971A patent/IL288971A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220296590A1 (en) | 2022-09-22 |
WO2021007636A1 (pt) | 2021-01-21 |
BR112021024894A2 (pt) | 2022-01-25 |
EP4001282A4 (en) | 2023-07-19 |
CN114158266A (zh) | 2022-03-08 |
EP4001282A1 (en) | 2022-05-25 |
IL288971A (en) | 2022-02-01 |
AR119407A1 (es) | 2021-12-15 |
JP2022540866A (ja) | 2022-09-20 |
CA3144770A1 (en) | 2021-01-21 |
KR20220035048A (ko) | 2022-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201900874B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
MY147364A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
GEP20227359B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
UA99361C2 (uk) | ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR | |
MY147628A (en) | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
TW200510380A (en) | Mitotic kinesin inhibitors | |
SG10201809260XA (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
MX2007007103A (es) | Derivados espiro como inhibidores de lipoxigenasa. | |
MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
MX2009013218A (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus. | |
ATE443063T1 (de) | Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen | |
NO20072546L (no) | Imidazo[4,5-b]pyridin-2-on og oksazolo[4,5-B]pyridin-2-on forbindelser og analoger derav som terapeutiske forbindelser | |
GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
ATE384701T1 (de) | Isochinolinone als kalium-kanal-inhibitoren | |
PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
MX2007003603A (es) | Metodos para preparar compuestos de indazol. | |
SI2054418T1 (sl) | Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
MY150747A (en) | Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
MX2022007442A (es) | Inhibidores de la proteina leucemia once-diecinueve (enl)/af9 yeats. | |
MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
MXPA05013210A (es) | Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos. | |
MX2022000939A (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos. |